Repligen

Repligen is a company that specializes in bioprocessing applications and solutions, providing a comprehensive range of products including upstream and downstream filtration, chromatography, fluid management, cell culture supplements, ligands, and analytics. The company focuses on process intensification to improve productivity, environmental, and economic metrics. Repligen offers solutions for process intensification, advanced therapy medical products (ATMP), ultrafiltration/diafiltration, continuous manufacturing, and fluid management. They develop and commercialize high-value products and flexible solutions for the production of biologic drugs, and provide technology breakthroughs and scalable hardware, software, and consumables workflow solutions for the development and manufacture of plasmid DNA, viral vectors, mRNA, and new modalities such as whole cells and cultivated meat. Repligen also offers single-use bioprocessing bags and assemblies through the acquisition of FlexBiosys Inc. and has launched TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device. The company acquired Metenova, a Swedish innovator in magnetic mixing technology for biopharmaceutical production, and provides in-line GMP testing solutions with the CTech™ FlowVPX® spectrophotometer system. Repligen offers a variety of ready-to-use dialysis devices, including SpectraPor Float-A-Lyzer, SpectraPor Micro Float-A-Lyzer®, and SpectraPor Tube-A-Lyzer, and manufactures Protein A ligands used in the purification of monoclonal antibodies. The company operates a state-of-the-art Gene Therapy Applications Center focused on developing internal applications expertise and effective collaborations with customers and gene therapy leaders. Repligen provides scalable dynamic dialysis systems through SpectraFlo™ Dynamic Dialysis Systems and offers a comprehensive range of chromatography products, including KRM Chromatography Systems and OPUS Pre-packed Columns. They also provide solutions for the development and production of mRNA and lipid nanoparticles (LNPs) for vaccines and therapies. Repligen has a significant presence in the global market with major manufacturing sites in the United States, Sweden, France, The Netherlands, Germany, and Estonia, and markets products globally through a direct commercial organization in the United States, Europe, and Asia, as well as through strategic partners and distributors in select markets. The company focuses on cost and process efficiencies to deliver innovative technologies and solutions in bioprocessing and offers hands-on process and implementation consultation from global Field Applications Specialists and recognized industry experts.